{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T13:03:26Z","timestamp":1770815006006,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021686","name":"Safeway Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Determine the association between the Breast Cancer Surveillance Consortium v2 model (BCSC) risk score and advanced and non-advanced invasive breast cancer (IBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated BCSC 5-year invasive breast cancer risk for 11,915 participants in a prospective screening cohort with median follow-up of 6.9\u00a0years prior to breast cancer diagnosis. Individuals in the top 25% by age of BCSC risk standard were considered high-risk, those in the bottom 75% low-risk.<\/jats:p>\n                    <jats:p>We obtained cancer outcomes, including American Joint Committee on Cancer (AJCC) prognostic pathologic stage, from the San Francisco Mammography Registry and an institutional cancer registry. We examined the associations of BCSC risk scores with advanced (\u2265\u2009AJCC prognostic stage II) and non-advanced (AJCC prognostic stage I) IBC using Fisher\u2019s exact test and logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 11,915 participants, 4,005 (34%) were high-risk. There were 254 incident IBC cases, of which 40 (16%) were advanced and 214 (84%) were non-advanced. The median 5-year BCSC risk score for women with and without IBC was 1.83% and 1.45%, respectively (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). High BCSC risk among women diagnosed with breast cancer was associated with non-advanced cancer (OR\u2009=\u20092.25, 95% CI\u2009=\u20091.71\u20132.95,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), but not with advanced cancer (OR\u2009=\u20091.20, 95% CI\u2009=\u20090.63\u20132.29,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.57) compared to women not diagnosed with breast cancer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>High BCSC risk scores were associated with high rates of non-advanced IBC. As non-advanced cancers are more likely to be hormone receptor-positive, BCSC may optimally identify candidates for endocrine risk reduction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-025-07894-1","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T08:34:47Z","timestamp":1769589287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network"],"prefix":"10.1007","volume":"215","author":[{"given":"Katherine","family":"Leggat-Barr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiyuri","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Tice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elene","family":"Tsopurashvili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosalyn","family":"Sayaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paige","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathy","family":"Malvin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah","family":"Sabacan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Perry-Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Theiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Acerbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander D.","family":"Borowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celia","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison Stover","family":"Fiscalini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karla","family":"Kerlikowske","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwey","family":"Shieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"van\u2019t Veer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,28]]},"reference":[{"key":"7894_CR1","unstructured":"Center for Disease Control and Prevention (2023) Basic Information About Breast Cancer. In: Cent. Dis. Control Prev. https:\/\/www.cdc.gov\/cancer\/breast\/basic_info\/index.htm. Accessed 22 Sept 2023"},{"key":"7894_CR2","unstructured":"United States Preventive Services Task Force | JAMA Network. https:\/\/jamanetwork.com\/collections\/44068\/united-states-preventive-services-task-force. Accessed 29 Sept 2024"},{"key":"7894_CR3","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jacr.2017.11.034","volume":"15","author":"DL Monticciolo","year":"2018","unstructured":"Monticciolo DL, Newell MS, Moy L et al (2018) Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. J Am Coll Radiol 15:408\u2013414. https:\/\/doi.org\/10.1016\/j.jacr.2017.11.034","journal-title":"J Am Coll Radiol"},{"key":"7894_CR4","unstructured":"ACS Breast Cancer Screening Guidelines. https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/screening-tests-and-early-detection\/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed 15 Jul 2025"},{"key":"7894_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1001\/jamainternmed.2021.0157","volume":"181","author":"NS Patel","year":"2021","unstructured":"Patel NS, Lee M, Marti JL (2021) Assessment of screening mammography recommendations by breast cancer centers in the US. JAMA Intern Med 181:717\u2013719. https:\/\/doi.org\/10.1001\/jamainternmed.2021.0157","journal-title":"JAMA Intern Med"},{"key":"7894_CR6","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1200\/JCO.22.02170","volume":"41","author":"J Star","year":"2023","unstructured":"Star J, Bandi P, Siegel RL et al (2023) Cancer screening in the United States during the second year of the COVID-19 pandemic. J Clin Oncol 41:4352\u20134359. https:\/\/doi.org\/10.1200\/JCO.22.02170","journal-title":"J Clin Oncol"},{"key":"7894_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-017-0035-5","volume":"3","author":"LJ Esserman","year":"2017","unstructured":"Esserman LJ (2017) The WISDOM study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer 3:1\u20137. https:\/\/doi.org\/10.1038\/s41523-017-0035-5","journal-title":"NPJ Breast Cancer"},{"key":"7894_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10549-019-05167-2","volume":"175","author":"JA Tice","year":"2019","unstructured":"Tice JA, Bissell MCS, Miglioretti DL et al (2019) Validation of the breast cancer surveillance consortium model of breast cancer risk. Breast Cancer Res Treat 175:519\u2013523. https:\/\/doi.org\/10.1007\/s10549-019-05167-2","journal-title":"Breast Cancer Res Treat"},{"key":"7894_CR9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.nurpra.2016.07.027","volume":"12","author":"DO Himes","year":"2016","unstructured":"Himes DO, Root AE, Gammon A, Luthy KE (2016) Breast cancer risk assessment: calculating lifetime risk using the Tyrer-Cuzick model. J Nurse Pract 12:581\u2013592. https:\/\/doi.org\/10.1016\/j.nurpra.2016.07.027","journal-title":"J Nurse Pract"},{"key":"7894_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/jnci\/93.5.358","volume":"93","author":"B Rockhill","year":"2001","unstructured":"Rockhill B, Spiegelman D, Byrne C et al (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358\u2013366. https:\/\/doi.org\/10.1093\/jnci\/93.5.358","journal-title":"J Natl Cancer Inst"},{"key":"7894_CR11","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1148\/radiol.2021203633","volume":"299","author":"SGA Veenhuizen","year":"2021","unstructured":"Veenhuizen SGA, de Lange SV, Bakker MF et al (2021) Supplemental breast MRI for women with extremely dense breasts: results of the second screening round of the DENSE trial. Radiology 299:278\u2013286. https:\/\/doi.org\/10.1148\/radiol.2021203633","journal-title":"Radiology"},{"key":"7894_CR12","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1200\/JCO.2015.60.8869","volume":"33","author":"JA Tice","year":"2015","unstructured":"Tice JA, Miglioretti DL, Li C-S et al (2015) Breast density and benign breast disease: risk assessment to identify women at high risk of breast cancer. J Clin Oncol 33:3137\u20133143. https:\/\/doi.org\/10.1200\/JCO.2015.60.8869","journal-title":"J Clin Oncol"},{"key":"7894_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/jama.2009.1498","volume":"302","author":"L Esserman","year":"2009","unstructured":"Esserman L, Shieh Y, Thompson I (2009) Rethinking screening for breast cancer and prostate cancer. JAMA 302:1685\u20131692. https:\/\/doi.org\/10.1001\/jama.2009.1498","journal-title":"JAMA"},{"key":"7894_CR14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1093\/jnci\/djaa176","volume":"113","author":"K Kerlikowske","year":"2021","unstructured":"Kerlikowske K, Bissell MCS, Sprague BL et al (2021) Advanced breast cancer definitions by staging system examined in the breast cancer surveillance consortium. J Natl Cancer Inst 113:909\u2013916. https:\/\/doi.org\/10.1093\/jnci\/djaa176","journal-title":"J Natl Cancer Inst"},{"key":"7894_CR15","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1016\/S0140-6736(13)60140-3","volume":"381","author":"J Cuzick","year":"2013","unstructured":"Cuzick J, Sestak I, Bonanni B et al (2013) Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 381:1827\u20131834. https:\/\/doi.org\/10.1016\/S0140-6736(13)60140-3","journal-title":"Lancet"},{"key":"7894_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086858","volume":"9","author":"E Vilaprinyo","year":"2014","unstructured":"Vilaprinyo E, Forn\u00e9 C, Carles M et al (2014) Cost-effectiveness and harm-benefit analyses of risk-based screening strategies for breast cancer. PLoS ONE 9:e86858. https:\/\/doi.org\/10.1371\/journal.pone.0086858","journal-title":"PLoS ONE"},{"key":"7894_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/jnci\/djac008","volume":"114","author":"K Kerlikowske","year":"2022","unstructured":"Kerlikowske K, Chen S, Golmakani MK et al (2022) Cumulative advanced breast cancer risk prediction model developed in a screening mammography population. J Natl Cancer Inst 114:676\u2013685. https:\/\/doi.org\/10.1093\/jnci\/djac008","journal-title":"J Natl Cancer Inst"},{"key":"7894_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/jamaoncol.2017.4298","volume":"4","author":"A Weiss","year":"2018","unstructured":"Weiss A, Chavez-MacGregor M, Lichtensztajn DY et al (2018) Validation study of the American Joint Committee on Cancer Eighth Edition prognostic stage compared with the anatomic stage in breast cancer. JAMA Oncol 4:203\u2013209. https:\/\/doi.org\/10.1001\/jamaoncol.2017.4298","journal-title":"JAMA Oncol"},{"key":"7894_CR19","unstructured":"Edge S, Byrd D, Compton C, et al AJCC Cancer Staging Handbook"},{"key":"7894_CR20","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-013-2612-0","volume":"140","author":"SL Elson","year":"2013","unstructured":"Elson SL, Hiatt RA, Anton-Culver H et al (2013) The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast Cancer Res Treat 140:417\u2013425. https:\/\/doi.org\/10.1007\/s10549-013-2612-0","journal-title":"Breast Cancer Res Treat"},{"key":"7894_CR21","unstructured":"San Francisco Mammography Registry. In: San Franc. Mammogr. Regist. https:\/\/mammography.ucsf.edu\/about. Accessed 13 Aug 2025"},{"key":"7894_CR22","unstructured":"Magny SJ, Shikhman R, Keppke AL (2025) Breast imaging reporting and data system. In: StatPearls. StatPearls Publishing. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459169\/"},{"key":"7894_CR23","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/EDBK_201313","volume":"38","author":"GN Hortobagyi","year":"2018","unstructured":"Hortobagyi GN, Edge SB, Giuliano A (2018) New and important changes in the TNM staging system for breast cancer. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet 38:457\u2013467. https:\/\/doi.org\/10.1200\/EDBK_201313","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"key":"7894_CR24","unstructured":"Stevenson M, Sergeant E, Heuer C, et al (2024) epiR: Tools for the Analysis of Epidemiological Data"},{"key":"7894_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/bjsopen\/zrac025","volume":"6","author":"G-Q Li","year":"2022","unstructured":"Li G-Q, Yu Y, Zhang W-W et al (2022) Impact of AJCC prognostic staging on prognosis and postmastectomy radiotherapy decision-making in hormone receptor-positive and HER2-positive breast cancer. BJS Open 6:zrac025. https:\/\/doi.org\/10.1093\/bjsopen\/zrac025","journal-title":"BJS Open"},{"key":"7894_CR26","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1200\/JCO.19.01472","volume":"37","author":"K Visvanathan","year":"2019","unstructured":"Visvanathan K, Fabian CJ, Bantug E et al (2019) Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol 37:3152\u20133165. https:\/\/doi.org\/10.1200\/JCO.19.01472","journal-title":"J Clin Oncol"},{"key":"7894_CR27","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1021\/tx060126v","volume":"19","author":"TS Dowers","year":"2006","unstructured":"Dowers TS, Qin Z-H, Thatcher GRJ, Bolton JL (2006) Bioactivation of selective estrogen receptor modulators (SERMs). Chem Res Toxicol 19:1125\u20131137. https:\/\/doi.org\/10.1021\/tx060126v","journal-title":"Chem Res Toxicol"},{"key":"7894_CR28","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.22.01153","volume":"41","author":"CM Vachon","year":"2023","unstructured":"Vachon CM, Scott CG, Norman AD et al (2023) Impact of artificial intelligence system and volumetric density on risk prediction of interval, screen-detected, and advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 41:3172\u20133183. https:\/\/doi.org\/10.1200\/JCO.22.01153","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7894_CR29","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10549-011-1670-4","volume":"132","author":"C Lin","year":"2012","unstructured":"Lin C, Buxton MB, Moore D et al (2012) Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 TRIAL (CALGB 150007\/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat 132:871\u2013879. https:\/\/doi.org\/10.1007\/s10549-011-1670-4","journal-title":"Breast Cancer Res Treat"},{"key":"7894_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.breast.2006.05.006","volume":"16","author":"P Bord\u00e1s","year":"2007","unstructured":"Bord\u00e1s P, Jonsson H, Nystr\u00f6m L, Lenner P (2007) Survival from invasive breast cancer among interval cases in the mammography screening programmes of northern Sweden. Breast Edinb Scotl 16:47\u201354. https:\/\/doi.org\/10.1016\/j.breast.2006.05.006","journal-title":"Breast Edinb Scotl"},{"key":"7894_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00306-9","volume":"7","author":"YS Huilgol","year":"2021","unstructured":"Huilgol YS, Keane H, Shieh Y et al (2021) Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. Npj Breast Cancer 7:102. https:\/\/doi.org\/10.1038\/s41523-021-00306-9","journal-title":"Npj Breast Cancer"},{"key":"7894_CR32","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1001\/jama.2019.11885","volume":"322","author":"DK Owens","year":"2019","unstructured":"US Preventive Services Task Force, Owens DK, Davidson KW et al (2019) Medication use to reduce risk of breast cancer: US preventive services task force recommendation statement. JAMA 322:857\u2013867. https:\/\/doi.org\/10.1001\/jama.2019.11885","journal-title":"JAMA"},{"key":"7894_CR33","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky067","volume":"2","author":"M Eklund","year":"2019","unstructured":"Eklund M, Broglio K, Yau C et al (2019) The WISDOM personalized breast cancer screening trial: simulation study to assess potential bias and analytic approaches. JNCI Cancer Spectr 2:pky067. https:\/\/doi.org\/10.1093\/jncics\/pky067","journal-title":"JNCI Cancer Spectr"},{"key":"7894_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw290","author":"Y Shieh","year":"2017","unstructured":"Shieh Y, Eklund M, Madlensky L et al (2017) Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw290","journal-title":"J Natl Cancer Inst"},{"key":"7894_CR35","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv036","volume":"107","author":"N Mavaddat","year":"2015","unstructured":"Mavaddat N, Pharoah PDP, Michailidou K et al (2015) Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst 107:djv036. https:\/\/doi.org\/10.1093\/jnci\/djv036","journal-title":"J Natl Cancer Inst"},{"key":"7894_CR36","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/JCO.22.01978","volume":"41","author":"JMN Lopes Cardozo","year":"2023","unstructured":"Lopes Cardozo JMN, Andrulis IL, Bojesen SE et al (2023) Associations of a breast cancer polygenic risk score with tumor characteristics and survival. J Clin Oncol Off J Am Soc Clin Oncol 41:1849\u20131863. https:\/\/doi.org\/10.1200\/JCO.22.01978","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"7894_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00382-z","volume":"7","author":"Y Shieh","year":"2023","unstructured":"Shieh Y, Roger J, Yau C et al (2023) Development and testing of a polygenic risk score for breast cancer aggressiveness. npj Precis Oncol 7:42. https:\/\/doi.org\/10.1038\/s41698-023-00382-z","journal-title":"npj Precis Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07894-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07894-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07894-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T09:28:51Z","timestamp":1770802131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07894-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,28]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7894"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07894-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,28]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.E. is a member of the BCBS Medical Advisory Panel. L.v.V is a part-time employee and stockholder Agendia NV; Consultant and stockholder ExaiBio Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}